NCT00546078 - Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

January 14, 2008

Primary Completion Date

December 22, 2008

Study Completion Date

December 1, 2009

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix™

Intramuscular injection, one or three doses

Trial Locations (17)

15241

GSK Investigational Site, Pittsburgh

16127

GSK Investigational Site, Grove City

19107

GSK Investigational Site, Philadelphia

40004

GSK Investigational Site, Bardstown

40202

GSK Investigational Site, Louisville

54449

GSK Investigational Site, Marshfield

78205

GSK Investigational Site, San Antonio

84109

GSK Investigational Site, Salt Lake City

87131

GSK Investigational Site, Albuquerque

94118

GSK Investigational Site, San Francisco

97210

GSK Investigational Site, Portland

98105

GSK Investigational Site, Seattle

T6G 2C8

GSK Investigational Site, Edmonton

V3A 4H9

GSK Investigational Site, Langley

R3E 0J9

GSK Investigational Site, Winnipeg

M4N 3M5

GSK Investigational Site, Toronto

30912-3500

GSK Investigational Site, Augusta